Eckert & Ziegler stock slips ahead of November 12 results

Published on 11/10/2026 at 17:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eckert & Ziegler stock traded at 13.81 euros on Tuesday before the next results date. Investors now await the November 12 report.

What investors should watch next

Eckert & Ziegler is scheduled to release third-quarter results on November 12.
Global Banking & Finance Review lists a revenue estimate of EUR 78.8 million for the upcoming report.
Radiopharmaceutical products and Actinium-225 supply remain key operating themes for investors.

Eckert & Ziegler, DE0005659700, Illustration mit AI erstellt.

Eckert & Ziegler stock traded at 13.81 euros on Lang & Schwarz at 17:14 CET on Tuesday, November 10, 2026, 0.14 percent below the Xetra close of Monday, November 9. The quote was 1.50 percent below the EUR 14.02 level cited in the latest pre-market report published at 08:45 CET on Tuesday, giving investors a fresh short-term comparison ahead of the next results.

Results date sets near-term catalyst

Global Banking & Finance Review lists November 12 as Eckert & Ziegler's next reporting date and cites a revenue estimate of EUR 78.8 million. The report will give investors a new indication of demand, margins and the pace of the expected operating recovery.

The upcoming release is the main near-term event for the stock. Management commentary on full-year expectations and the performance of the two operating segments will be central to the market's assessment.

Radiopharma remains strategic focus

Eckert & Ziegler develops isotope technology for cancer treatment, industrial radiometry and nuclear medicine diagnostics and therapy. Its operating business is divided into Medical and Isotope Products, according to the Eckert & Ziegler investor relations page.

The same company overview reports 2025 revenue of EUR 312.0 million and adjusted EBIT of EUR 77.7 million. Investors will therefore focus on whether the third-quarter figures show progress against the group's operating recovery plans.